OSLO, Norway, April 28, 2025 /PRNewswire/ -- Oncoinvent ASA, a clinical-stage radiopharmaceutical company developing innovative treatments for solid cancers, today announced the 18-month follow-up results from its Phase 1 clinical trial (RAD-18-001) evaluating Radspherin® in patients with...
Hence then, the article about oncoinvent reports updated 18 month data from phase 1 ovarian cancer trial with radspherin no new recurrences demonstrate continued promise of preventing disease progression was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Oncoinvent Reports updated 18-Month Data from Phase 1 Ovarian Cancer Trial with Radspherin®: No new recurrences Demonstrate Continued Promise of Preventing Disease Progression )
Also on site :
- Physicists just witnessed pinpricks of darkness moving faster than the speed of light — without breaking the laws of relativity
- China has so far weathered the historic oil crisis. But as Xi prepares to meet Trump, costs are starting to grow
- 1967 Classic Rock Anthem Ranked Among the ‘Greatest Songs of All Time’—‘One of the Most Beautiful Songs Ever Written’